We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
High-ranking FDA officials visiting India have laid out a new approach to facility inspections for Indian manufacturers that would reward firms if their quality management system exceeds minimum compliance requirements. Read More
The U.S. Supreme Court has declined to hear one of three petitions submitted over a Pennsylvania appellate decision refusing to recognize generic drugs as largely immune from product liability lawsuits. Read More
Generics maker Glenmark might have infringed on Merck’s Indian patent covering type II diabetes drugs Januvia and Janumet, the Delhi High Court in India said recently in an interim ruling. Read More
European regulators are establishing a task force that will advise on planning, developing, implementing and maintaining international standards on drug product identification. Read More
Drugmakers seeking approval of genetically engineered products must begin submitting an assessment with their applications that evaluates whether they would be harmful if released into the environment. Read More
Drugmakers may use pharmacokinetic bioequivalence studies to compare how two orally-inhaled drugs with the same active substance disperse in the lungs, the European Medicines Agency says. Read More
A federal appeals court has affirmed a lower court ruling that Allergan’s Zymar eye drop patent is invalid because the process is obvious for others to try. The decision paves the way for generic versions of the drug. Read More
The FTC signed off on a divestiture order allowing Sun Pharma’s imminent $4 billion purchase of fellow Indian generics maker Ranbaxy to go forward as long as the companies relinquish rights to the antibiotic minocycline. Read More
Médecins Sans Frontières is urging Indian generics makers to reject a program Gilead plans to implement in developing countries to prevent illegal diversion of its hepatitis C drugs to more lucrative markets. Read More